Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

Journal of Immunology

Volumn 176, Issue 12, 2006, Pages 7335-7345

  Zaks, Karen ^a   Jordan, Michael ^a   Guth, Amanda ^a   Sellins, Karen ^a   Kedl, Ross ^b   Izzo, Angelo ^a   Bosio, Catharine ^a   Dow, Steven ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE; LIPOSOME; MELANOMA ANTIGEN; MYCOBACTERIUM ANTIGEN; NUCLEIC ACID; OVALBUMIN; PLASMID DNA; RESIQUIMOD; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 STIMULATING AGENT; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 STIMULATING AGENT; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOSTIMULATION; MELANOMA; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 33744903928     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.12.7335     Document Type: Article

References (71)

1. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
2. Reis e Sousa, C. 2004. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin. Immunol. 16: 27-34.
3. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
4. Cook, D. N., D. S. Pisetsky, and D. A. Schwartz. 2004. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 5: 975-995.
5. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
6. Petrovsky, N., and J. C. Aguilar. 2004. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82: 488-496.
7. O'Hagan, D. T. 2001. Recent developments in vaccine delivery systems. Curr. Drug Targets Infect. Disord. 1: 273-286.
8. Pashine, A., N. M. Valiante, and J. B. Ulmer. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11: S63-S68.
9. Schijns, V. E. 2003. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 21: 829-831.
10. O'Hagan, D. T., and N. M. Valiante. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2: 727-735.
11. Singh, M., and D. T. O'Hagan. 2002. Recent advances in vaccine adjuvants. Pharm. Res. 19: 715-728.
12. Tudor, D., C. Dubuquoy, V. Gaboriau, F. Lefevre, B. Charley, and S. Riffault. 2005. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 23: 1258-1264.
13. Evans, J. T., C. W. Cluff, D. A. Johnson, M. J. Lacy, D. H. Persing, and J. R. Baldridge. 2003. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2: 219-229.
14. Klinman, D. M. 2003. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2: 305-315.
15. Krieg, A. M. 2000. Immune effects and mechanisms of action of CpG motifs. Vaccine 19: 618-622.
16. Marciani, D. J. 2003. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8: 934-943.
17. Ishii, N., J. Fukushima, T. Kaneko, E. Okada, K. Tani, S. I. Tanaka, K. Hamajima, K. Q. Xin, S. Kawamoto, W. Koff, et al. 1997. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 13: 1421-1428.
18. Whitmore, M., S. Li, and L. Huang. 1999. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene. Ther. 6: 1867-1875.
19. Gursel, I., M. Gursel, K. J. Ishii, and D. M. Klinman. 2001. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167: 3324-3328.
20. Dow, S. W., L. G. Fradkin, D. H. Liggitt, A. P. Willson, T. D. Heath, and T. A. Potter. 1999. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163: 1552-1561.
21. -DNA complexes. Mol. Ther. 12: 451-459.
22. Rocha, A., S. Ruiz, and J. M. Coll. 2002. Improvement of DNA transfection with cationic liposomes. J. Physiol. Biochem. 58: 45-56.
23. Briane, D., D. Lesage, A. Cao, R. Coudert, N. Lievre, J. L. Salzmann, and E. Taillandier. 2002. Cellular pathway of plasmids vectorized by cholesterol-based cationic liposomes. J. Histochem. Cytochem. 50: 983-991.
24. Wagner, H. 2004. The immunobiology of the TLR9 subfamily. Trends Immunol. 25: 381-386.
25. Chikh, G., and M. P. Schutze-Redelmeier. 2002. Liposomal delivery of CTL epitopes to dendritic cells. Biosci. Rep. 22: 339-353.
26. Raychaudhuri, S., M. Tonks, F. Carbone, T. Ryskamp, W. J. Morrow, and N. Hanna. 1992. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc. Natl. Acad. Sci. USA 89: 8308-8312.
27. Jiang, Z. H., and R. R. Koganty. 2003. Synthetic vaccines: the role of adjuvants in immune targeting. Curr. Med. Chem. 10: 1423-1439.
28. Moingeon, P., J. Haensler, and A. Lindberg. 2001. Towards the rational design of Th1 adjuvants. Vaccine 19; 4363-4372.
29. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344: 873-875.
30. Villacres, M. C., S. Behboudi, T. Nikkila, K. Lovgren-Bengtsson, and B. Morein. 1998. Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction. Cell. Immunol. 185: 30-38.
31. Miconnet, I., S. Koenig, D. Speiser, A. Krieg, P. Guillaume, J. C. Cerottini, and P. Romero. 2002. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168: 1212-1218.
32. Klinman, D. M., D. Currie, I. Gursel, and D. Verthelyi. 2004. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199: 201-216.
33. Mesa, C., and L. E. Fernandez. 2004. Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell Biol. 82: 644-650.
34. Moron, G., G. Dadaglio, and C. Leclerc. 2004. New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 25: 92-97.
35. Alving, C. R. 2002. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20(Suppl. 3): S56-S64.
36. Burdin, N., B. Guy, and P. Moingeon. 2004. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 18: 79-93.
37. Ulmer, J. B. 2002. Toward the development of better vaccine adjuvants. Expert Opin. Biol. Ther. 2: 119-121.
38. Schijns, V. E., and A. Tangeras. 2005. Vaccine adjuvant technology: from theoretical mechanisms to practical approaches. Dev. Biol. 121: 127-134.
39. Roland, K. L., S. A. Tinge, K. P. Killeen, and S. K. Kochi. 2005. Recent advances in the development of live, attenuated bacterial vectors. Curr. Opin. Mol. Ther. 7: 62-72.
40. Suzuki, Y., D. Wakita, K. Chamoto, Y. Narita, T. Tsuji, T. Takeshima, H. Gyobu, Y. Kawarada, S. Kondo, S. Akira, et al. 2004. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64: 8754-8760.
41. Dileo, J., R. Banerjee, M. Whitmore, J. V. Nayak, L. D. Falo, Jr., and L. Huang. 2003. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol. Ther. 1: 640-648.
42. Cui, Z., and L. Huang. 2005. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol. Immunother. 12: 1180-1190.
43. Gursel, M., S. Tunca, M. Ozkan, G. Ozcengiz, and G. Alaeddinoglu. 1999. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine 17: 1376-1383.
44. Fairman, J., L. Roche, I. Pieslak, M. Lay, S. Corson, E. Fox, C. Luong, G. Koe, B. Lemos, R. Grove, et al. 1999. Quantitative RT-PCR to evaluate in vivo expression of multiple transgenes using a common intron. BioTechniques 27: 566-570.
45. Templeton, N. S., D. D. Lasic, P. M. Frederik, H. H. Strey, D. D. Roberts, and G. N. Pavlakis. 1997. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15: 647-652.
46. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
47. Fisher, J. H., J. Larson, C. Cool, and S. W. Dow. 2002. Lymphocyte activation in the lungs of SP-D null mice. Am. J. Respir. Cell Mol. Biol. 27: 24-33.
48. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199: 775-784.
49. Meyer, A. L., C. Trollmo, F. Crawford, P. Marrack, A. C. Steere, B. T. Huber, J. Kappler, and D. A. Hafler. 2000. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc. Natl. Acad. Sci. USA 97: 11433-11438.
50. Geissmann, F., S. Jung, and D. R. Littman. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82.
51. Jordan, M. B., D. M. Mills, J. Kappler, P. Marrack, and J. C. Cambier. 2004. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304: 1808-1810.
52. Lauvau, G., S. Vijh, P. Kong, T. Horng, K. Kerksiek, N. Serbina, R. A. Tuma, and E. G. Pamer. 2001. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294: 1735-1739.
53. Gourley, T. S., E. J. Wherry, D. Masopust, and R. Ahmed. 2004. Generation and maintenance of immunological memory. Semin. Immunol. 16: 323-333.
54. Masopust, D., and R. Ahmed. 2004. Reflections on CD8 T-cell activation and memory. Immunol. Res. 29: 151-160.
55. Beignon, A. S., M. Skoberne, and N. Bhardwaj. 2003. Type I interferons promote cross-priming: more functions for old cytokines. Nat. Immunol. 4: 939-941.
56. + T lymphocytes by immunostimulatory DNA-based vaccines. J. Immunol. 168: 4907-4913.
57. Pardoll, D. M. 2002. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2: 227-238.
58. Brandt, L., M. Elhay, I. Rosenkrands, E. B. Lindblad, and P. Andersen. 2000. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68: 791-795.
59. Mollenkopf, H. J., D. Groine-Triebkorn, P. Andersen, J. Hess, and S. H. Kaufmann. 2001. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine 19: 4028-4035.
60. Olsen, A. W., P. R. Hansen, A. Holm, and P. Andersen. 2000. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur. J. Immunol. 30: 1724-1732.
61. Eriksson, K., and J. Holmgren. 2002. Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol. 14: 666-672.
62. Felnerova, D., J. F. Viret, R. Gluck, and C. Moser. 2004. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15: 518-529.
63. Gregoriadis, G., B. McCormack, M. Obrenovic, R. Saffie, B. Zadi, and Y. Perrie. 1999. Vaccine entrapment in liposomes. Methods 19: 156-162.
64. Reis e Sousa, C., and R. N. Germain. 1995. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182: 841-851.
65. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
66. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
67. Schulz, O., S. S. Diebold, M. Chen, T. I. Naslund, M. A. Nolte, L. Alexopoulou, Y. T. Azuma, R. A. Flavell, P. Liljestrom, and C. Reis e Sousa. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
68. Santini, S. M., T. Di Pucchio, C. Lapenta, S. Parlato, M. Logozzi, and F. Belardelli. 2002. The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity. J. Interferon Cytokine Res. 22: 1071-1080.
69. Demangel, C., J. Zhou, A. B. Choo, G. Shoebridge, G. M. Halliday, and W. J. Britton. 2005. Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol. Immunol. 42: 979-885.
70. van Broekhoven, C. L., C. R. Parish, C. Demangel, W. J. Britton, and J. G. Altin. 2004. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64: 4357-4365.
71. Mueller, R. S., J. Veir, K. V. Fieseler, and S. W. Dow. 2005. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis: a pilot study. Vet. Dermatol. 16: 61-68.